Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Rene Machietto; Nicholas Giacobbe; Jessica Perazzelli; Ted J. Hofmann; Allison Barz Leahy; Stephan A. Grupp; Yongping Wang; Stephan Kadauke

doi:10.3791/65488

Journal

/

Medicine

/

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

JoVE Journal
Medicine

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Medicine

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

2,255 Views

•

06:18 min

•

August 18, 2023

DOI:

10.3791/65488-v

DOI:

10.3791/65488-v

•

06:18 min

August 18, 2023

•

8 Views

Rene Machietto¹, Nicholas Giacobbe¹, Jessica Perazzelli², Ted J. Hofmann², Allison Barz Leahy^2,3, Stephan A. Grupp^1,2,3, Yongping Wang^1,3,4, Stephan Kadauke^1,3,4

¹Cell and Gene Therapy Laboratory, Department of Pathology and Laboratory Medicine,Children’s Hospital of Philadelphia, ²Division of Oncology, Department of Pediatrics,Children’s Hospital of Philadelphia, ³Perelman School of Medicine at the University of Pennsylvania, ⁴Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine,Children’s Hospital of Philadelphia

Transcript

The advantage of our protocol is that it is a semi-automated, closed system that still offers flexibility. The labor-intensive steps are replaced by the automation, which is run by a computer, and because it’s run by a computer, the user can customize their protocol. This is also all done in a closed system.

We found that the sort of stem cell laboratories that are commonly present in hospitals have the capability to produce clinical grade CAR-T cells at significantly lower cost than commercial alternatives. We think that our process could be easily adapted to make CAR-T cell specific for other targets, and also to manufacture other types of cell and gene therapies. Our team is poised to explore other CAR-T cell targets and new gene therapies.

On a broader scale, cell and gene therapies are rapidly expanding, and we are excited to continue to support and innovate in this exciting field.

Summary

This article details the manufacturing process for chimeric antigen receptor T cells for clinical use, specifically using an automated cell processor capable of performing viral transduction and cultivation of T cells. We provide recommendations and describe pitfalls that should be considered during the process development and implementation of an early-phase clinical trial.